MediWound Ltd. reported third quarter 2025 revenue of $5.4 million, an increase of 23% year-over-year. For the first nine months of 2025, the company recorded an operating loss of $17.5 million, compared to $13.3 million in the same period of 2024. Net loss for the period was $16.7 million, or $1.53 per share, down from $26.3 million, or $2.72 per share, in 2024, primarily due to non-cash financial income from warrant revaluation. Non-GAAP Adjusted EBITDA loss was $13.9 million, compared to a loss of $9.9 million in 2024. MediWound used $15.8 million in cash for operating activities during the first nine months of 2025 and ended September 30, 2025, with $60 million in cash, cash equivalents, and short-term deposits, up from $44 million at the end of 2024. Business developments included ongoing enrollment in the VALUE Phase III trial of EscharEx for venous leg ulcers and completion of commissioning for the expanded NexoBrid facility, with full operational capacity expected by year-end 2025. The company strengthened its balance sheet with a $30 million equity financing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9579550-en) on November 20, 2025, and is solely responsible for the information contained therein.
Comments